Targeting HMGB1 in the treatment of sepsis
Introduction: Sepsis refers to the host's deleterious and non-resolving systemic inflammatory
response to microbial infections and represents the leading cause of death in the intensive …
response to microbial infections and represents the leading cause of death in the intensive …
Therapeutic potential of HMGB1-targeting agents in sepsis
Sepsis refers to a systemic inflammatory response syndrome resulting from a microbial
infection. The inflammatory response is partly mediated by innate immune cells (such as …
infection. The inflammatory response is partly mediated by innate immune cells (such as …
HMGB1 as a therapeutic target for sepsis: it's all in the timing!
LF Gentile, LL Moldawer - Expert opinion on therapeutic targets, 2014 - Taylor & Francis
Morbidity and mortality from severe sepsis remain high, despite decades of research and
improvements in intensive care unit (ICU) care. There have been over 100 failed clinical …
improvements in intensive care unit (ICU) care. There have been over 100 failed clinical …
Endogenous regulation and pharmacological modulation of sepsis-induced HMGB1 release and action: An updated review
CS Zhu, W Wang, X Qiang, W Chen, X Lan, J Li… - Cells, 2021 - mdpi.com
Sepsis remains a common cause of death in intensive care units, accounting for
approximately 20% of total deaths worldwide. Its pathogenesis is partly attributable to …
approximately 20% of total deaths worldwide. Its pathogenesis is partly attributable to …
HMGB1 as a potential therapeutic target
Despite recent advances in antibiotic therapy and intensive care, sepsis remains the most
common cause of death in the intensive care units, claiming approximately 225 000 victims …
common cause of death in the intensive care units, claiming approximately 225 000 victims …
Novel HMGB1-inhibiting therapeutic agents for experimental sepsis
Sepsis refers to a systemic inflammatory response syndrome resulting from a microbial
infection. The inflammatory response is partly mediated by innate immune cells (such as …
infection. The inflammatory response is partly mediated by innate immune cells (such as …
Therapeutic targeting of HMGB1 during experimental sepsis modulates the inflammatory cytokine profile to one associated with improved clinical outcomes
NE Stevens, MJ Chapman, CK Fraser, TR Kuchel… - Scientific reports, 2017 - nature.com
Sepsis remains a significant health burden and a major clinical need exists for therapeutics
to dampen the excessive and uncontrolled immune activation. Nuclear protein high mobility …
to dampen the excessive and uncontrolled immune activation. Nuclear protein high mobility …
High mobility group box 1 protein as a potential drug target for infection-and injury-elicited inflammation
In response to infection or injury, a ubiquitous nucleosomal protein, HMGB1 is secreted
actively by innate immune cells, and/or released passively by injured/damaged cells …
actively by innate immune cells, and/or released passively by injured/damaged cells …
Bench to Bedside: HMGB1—A Novel Proinflammatory Cytokine and Potential Therapeutic Target for Septic Patients in the Emergency Department
Overwhelming gram‐negative bacterial infection and life‐threatening systemic inflammation
are widespread problems in critically ill emergency department patients. Currently, the …
are widespread problems in critically ill emergency department patients. Currently, the …
Targeting HMGB1 for the treatment of sepsis and sepsis-induced organ injury
C Deng, L Zhao, Z Yang, J Shang, C Wang… - Acta Pharmacologica …, 2022 - nature.com
High mobility group box 1 (HMGB1) is a ubiquitous nuclear protein that is present in almost
all cells and regulates the activity of innate immune responses in both intracellular and …
all cells and regulates the activity of innate immune responses in both intracellular and …